e-Therapeutics plc Management Update (8368J)

TIDMETX

RNS Number : 8368J

e-Therapeutics plc

14 September 2016

e-Therapeutics plc

('e-Therapeutics' or 'the Company')

Management Update

Oxford, UK, 14 September 2016 - e-Therapeutics plc (AIM :ETX) announces that following its full year results statement on 22 March 2016 which highlighted the Company's strategic refocus on its discovery platform, Steve Self will stand down as Development Director and leave the Company on 30 September 2016.

Iain Ross, Executive Chairmen, commented: "Steve joined e-Therapeutics in December 2010 following a distinguished career at The Wellcome Foundation, Boots Healthcare and as R&D Director of Merck's Generic Global business. We thank him for his significant contribution to our activities and wish him continuing success in his new endeavours."

-Ends-

Contacts:

 
 e-Therapeutics plc                   Tel: +44 (0) 1993 883 
  Iain Ross, Chairman                  125 
  Steve Medlicott, Finance Director    www.etherapeutics.co.uk 
 Numis Securities Limited             Tel: +44 (0) 207 260 
  Michael Meade / Freddie Barnfield    1000 
  (Corporate Finance)                  www.numis.com 
  James Black (Corporate Broking) 
 Instinctif Partners                  Tel: +44 (0) 207 457 
  Melanie Toyne Sewell / Jayne         2020 
  Crook                                Email: e-therapeutics@instinctif.com

About e-Therapeutics plc

e-Therapeutics (AIM: ETX) is a drug discovery company with a proprietary discovery platform based on advances in network pharmacology and chemical biology.

The Company is applying its platform to the discovery of new drug candidates. The therapeutic focus of the Company's activity is in immuno-oncology, addressing drug resistance in targeted cancer therapies and anti-infectives. The platform is highly productive, yielding multiple potent and selective molecules at a much higher rate and more quickly than is reported for conventional drug discovery.

e-Therapeutics has a variety of preclinical stage assets, including ETX1153c, a functionally resistance-less antibiotic; ETS2300, telomerase inhibition in anti-cancer; ETS3100, small molecule anti-TNF<ALPHA>; ETS2400, Hedgehog pathway inhibition and ETS5200, broad spectrum antivirals. The Company has recently completed a phase IIb clinical trial for ETS6103, a drug to treat major depressive disorder.

The Company is fully funded to advance its drug discovery programmes. It is based in Oxford and Newcastle, UK. For more information, visit www.etherapeutics.co.uk.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCFZLFFQKFBBBQ

(END) Dow Jones Newswires

September 14, 2016 07:08 ET (11:08 GMT)

E-therapeutics (LSE:ETX)
Historical Stock Chart
From Apr 2024 to May 2024